Role of Amyloid Beta as Sensors and Protectors in Alzheimer’s and Other Diseases Explored
Data supports links between AD and diabetes, according to new study in the Journal of Alzheimer’s Disease
March 27, 2012
Alzheimer’s disease is the sixth leading cause of death in the United States and the only cause of death among the top 10 in America without a way to prevent, cure or even slow its progression, according to the Alzheimer’s Association. Today, 5.4 million Americans are living with the disease, and another American develops it every 69 seconds.
Unfortunately, many Alzheimer’s disease drugs targeting the misfolding of the amyloid beta protein have failed clinical trials, leading some to question the validity of the amyloid hypothesis.
In upcoming issues of the Journal of Alzheimer’s Disease, Dr. Ian Murray of the Texas A&M Health Science Center College of Medicine provides a new way of looking at amyloid – not only in Alzheimer’s, but also in other amyloid diseases – with a hypotheses paper and separate supporting data paper.
Murray, Ph.D., assistant professor in the Department of Neuroscience and Experimental Therapeutics in the college, is one of four authors on a hypotheses paper supporting Amyloids as Sensors and Protectors (ASAP). This hypothesis incorporates both the emerging idea that amyloid is protective and the pathological amyloid hypothesis.
Amyloid senses cellular environmental stress, such as elevation of reactive metabolites and oxidative products or metals, and then misfolds. This misfolding initiates a protective cellular response in the short term. Long-term or chronic stress such as metabolic dysfunction (diabetes) would lead to the pathological consequences of amyloid misfolding (as diabetes is a risk factor for Alzheimer’s).
This interesting ASAP hypothesis is supported by existing publications in the Alzheimer’s disease field, as well as from several other amyloid diseases. It also explains several disparate findings in the field and suggests further experiments to test the hypothesis.
In the supporting data paper, Dr. Murray and four other authors mechanistically linked diabetes and Alzheimer’s. They demonstrated the first part of the ASAP hypothesis – amyloid can detect metabolic dysfunction. Reactive metabolites, elevated during metabolic dysfunction such as diabetes, chemically modify and misfold the amyloid protein in the test tube. These metabolites play a role in chemical glycation reactions to eventually form advanced glycation end products.
Dr. Murray demonstrates, similar to previous reports, that such modifications localize to the misfolded amyloid in Alzheimer’s disease.
# # #
NOTES FOR EDITORS
The hypotheses paper will publish in the April issue of the Journal of Alzheimer’s Disease, the data paper in May. Both are currently in pre-press production and accessible without an embargo. Dr. Murray is available, as are PDF copies of the papers. Contact Daphne Watrin, IOS Press, at +31 20 688 3355, email@example.com. To interview the authors contact Scott Maier, Director of Media Relations, Marketing and Communications, Texas A&M Health Science Center, at 979 458 0770, firstname.lastname@example.org.
Petrofes-Chapa, RD, Emery, M, Fawver, JN, Murray, IVJ. Amyloids as Sensors and Protectors (ASAP) Hypothesis. J Alzheimer’s Dis. 2012, 29(3). DOI: 10.3233/JAD-2012-112015.
Fawver, JN, Schall, HE, Petrofes-Chapa, RD, Zhu, X, Murray, IVJ. Amyloid-β Metabolite Sensing: Biochemical Linking of
Glycation Modification and Misfolding. J Alzheimer’s Dis. 2012, 30(1). DOI: 10.3233/JAD-2012-112114.
ABOUT THE JOURNAL OF ALZHEIMER’S DISEASE (JAD)
The Journal of Alzheimer’s Disease (http://www.j-alz.com) is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. Groundbreaking research that has appeared in the journal includes novel therapeutic targets, mechanisms of disease and clinical trial outcomes. The Journal of Alzheimer’s Disease has an Impact Factor of 4.261 according to Thomson Reuters’ 2011 edition of Journal Citation Reports. It is ranked #19 on the Index Copernicus Top 100 Journal List. The Journal is published by IOS Press (www.iospress.com).
ABOUT IOS PRESS
Commencing its publishing activities in 1987, IOS Press (www.iospress.nl) serves the information needs of scientific and medical communities worldwide. IOS Press now (co-)publishes over 100 international journals and about 130 book titles each year on subjects ranging from computer sciences and mathematics to medicine and the natural sciences.
IOS Press continues its rapid growth, embracing new technologies for the timely dissemination of information. All journals are available electronically and an e-book platform was launched in 2005.
Headquartered in Amsterdam with satellite offices in the USA, Germany, India and China, IOS Press has established several strategic co-publishing initiatives. Notable acquisitions included Delft University Press in 2005 and Millpress Science Publishers in 2008.